Voltage-gated calcium channels and pain

Techniques in Regional Anesthesia and Pain Management

Volumn 14, Issue 2, 2010, Pages 42-47

  Doan, Lisa ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL N TYPE; CALCIUM CHANNEL T TYPE; ETHOSUXIMIDE; GABAPENTIN; LECONOTIDE; LIGAND; MESSENGER RNA; MIBEFRADIL; MORPHINE; NUCLEIC ACID; OMEGA CONOTOXIN; OMEGA CONOTOXIN MVIIA; PREGABALIN; SNX 482; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL;

AGRANULOCYTOSIS; ALLODYNIA; ARTICLE; CANCER PAIN; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC PAIN; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DIZZINESS; DROWSINESS; DRUG DOSE TITRATION; EPILEPSY; FIBROMYALGIA; GAIT DISORDER; GASTROINTESTINAL SYMPTOM; HUMAN; NAUSEA; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; ORTHOSTATIC HYPOTENSION; PERIPHERAL EDEMA; PROTEIN FUNCTION; PROTEIN STRUCTURE; SIDE EFFECT; SOMNOLENCE; STEVENS JOHNSON SYNDROME;

EID: 77953295174     PISSN: 1084208X     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.trap.2010.03.003     Document Type: Article

References (84)

1. Hardt J., Jacobsen C., Goldberg J., et al. Prevalence of chronic pain in a representative sample in the United States. Pain Med 9 (2008) 803-812
2. Ohayon M.M., and Schatzberg A.F. Chronic pain and major depressive disorder in the general population. J Psychiatr Res (2010) (in press)
3. Catterall W.A. Structure and regulation of voltage-gated Ca channels. Annu Rev Cell Dev Biol 16 (2000) 521-544
4. Perez-Reyes E., Sim H.S., Lacerda A.E., et al. Induction of calcium currents by the expression of the A1-subunit of the dihydropyridine receptor from skeletal muscle. Nature 340 (1989) 233-236
5. Varadi G., Lory P., Schultz D., et al. Acceleration of activation and inactivation by the b sununit of the skeletal muscle calcium channel. Nature 352 (1991) 159-162
6. Singer D., Biel M., Lotan I., et al. The roles of the subunits in the function of the calcium channel. Science 253 (1991) 1553-1667
7. Chu P.J., Robertson H.M., and Best P.M. Calcium channel γ subunits provide insights into the evolution of this gene family. Gene 280 (2001) 37-48
8. Westenbroek R.E., Hell J.W., Warner C., et al. Biochemical properties and subcellular distribution of an N-type calcium channel alpha 1 subunit. Neuron 9 (1992) 1099-1115
9. Maggi C.A., Tramontana M., Cecconi R., et al. Neurochemical evidence for the involvement of N-type calcium channels in transmitter secretion from peripheral endings of sensory nerves in Guinea pigs. Neurosci Lett 114 (1990) 203-206
10. Berridge M.J., Lipp P., and Bootman M.D. The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol 1 (2000) 11-21
11. Seward E., Hammond C., and Henderson G. m-opioid-receptor-mediated inhibition of the N-type calcium-channel current. Proc R Soc Lond B 244 (1991) 129-135
12. Bourinet E., Soong T.W., Stea A., et al. Determinants of the G protein-dependent opioid modulation of neuronal calcium channels. Proc Natl Acad Sci U S A 93 (1996) 1486-1491
13. Olivera B.M., McIntosh J.M., Cruz F.A., et al. Purification and sequence of a presynaptic peptide toxin from Conus geographus venom. Biochimie 23 (1984) 5087-5090
14. Olivera B.M., Cruz L.J., de Santos V., et al. Neuronal calcium channel antagonists. Discrimination between calcium channel subtypes using omega-conotoxin from conus Magus venom. Biochimie 26 (1987) 2086-2090
15. Chaplan S.R., Pogrel J.W., and Yaksh T.L. Role of voltage-dependent calcium channel subtypes in experimental tactile allodynia. J Pharmacol Exp Ther 269 (1994) 1117-1123
16. Diaz A., and Dickenson A.H. Blockade of spinal N- and P-type, but not L-type, calcium channels inhibits the excitability of rat dorsal horn neurones produced by subcutaneous formalin inflammation. Pain 69 (1997) 93-100
17. Matthews E.A., and Dickenson A.H. Effects of spinally delivered N- and P-type voltage-dependent calcium channel antagonists on dorsal horn neuronal responses in a rat model of neuropathy. Pain 92 (2001) 235-246
18. Evans A.R., Nicol G.D., and Vasko M.R. Differential regulation of evoked peptide release by voltage-sensitive calcium channels in rat sensory neurons. Brain Res 18 (1996) 265-273
19. Zieglgansberger W., and Tulloch I.F. Effects of substance P on neurones in the dorsal horn of the spinal cord of the cat. Brain Res 166 (1979) 273-282
20. Kuraishi Y., Hirota N., Sato Y., et al. Evidence that substance P and somatostatin transmit separate information related to pain in the spinal dorsal horn. Brain Res 325 (1985) 294-298
21. Piercey M.F., Moon M.W., Blinn J.R., et al. Analgesic activities of spinal cord substance P antagonists implicate substance P as a neurotransmitter of pain sensation. Brain Res 385 (1986) 74-85
22. Oku R., Satoh M., Fujii N., et al. Calcitonin gene-related peptide promotes mechanical nociception by potentiating release of substance P from the spinal dorsal horn in rats. Brain Res 403 (1987) 350-354
23. Saegusa H., Kurihara T., Zong S., et al. Supression of inflammatory and neuropathic pain symptoms in mice lacking the N-type Ca2+ channel. EMBO J 20 (2001) 2349-2356
24. Lipscombe D., Pan J.Q., and Gray A.C. Functional diversity in neuronal voltage-gated calcium channels by alternative splicing of Ca(v)alpha1. Mol Neurobiol 26 (2002) 21-44
25. Bell T.J., Thaler C., Castiglioni A.J., et al. Cell-specific alternative splicing increases calcium channel current density in the pain pathway. Neuron 41 (2004) 127-138
26. Altier C., Dale C.S., Kisilevsky A.E., et al. Differential role of N-type calcium channel Splice isoforms in pain. J Neurosci 27 (2007) 6363-6373
27. Atanassoff P.G., Hartmannsgruber M.W., Thrasher J., et al. Ziconotide, a new N-type calcium channel blocker, administered intrathecally for acute postoperative pain. Reg Anesth Pain Med 25 (2000) 274-278
28. Staats P.S., Yearwood T., Charapata S.G., et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS. J Am Med Assoc 291 (2004) 64-70
29. Rauck R.L., Wallace M.S., Leong M.S., et al. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manage 31 (2006) 393-406
30. Wallace M.S., Kosek P.S., Staats P., et al. Phase II, open-label, multicenter study of combined intrathecal morphine and ziconotide: Addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain. Pain Med 9 (2008) 271-281
31. Webster L.R., Fakata K.L., Charapata S., et al. Open-label, multicenter study of combined intrathecal morphine and ziconotide: Addition of morphine in patients receiving ziconotide for severe chronic pain. Pain Med 9 (2008) 282-290
32. McGuire D., Bowersox S., Fellmann J.D., et al. Sympatholysis after neuron-specific, N-type, voltage-sensitive calcium channel blockade: First Demonstration of N-channel function in human. J Cardiovasc Pharmacol 30 (1997) 400-403
33. Bowersox S.S., Singh T., Nadasdi L., et al. Cardiovascular effects of ω-conopeptides in conscious rats: Mechanisms of action. J Cardiovasc Pharmacol 20 (1992) 756-764
34. Smith M.T., Cabot P.J., Ross F.B., et al. The novel N-type calcium channel blocker, AM336, produces potent dose-dependent antinociception after intrathecal dosing in rats and inhibits substance P release in rat spinal cord slices. Pain 96 (2002) 119-127
35. Scott D.A., Wright C.E., and Angus J.A. Actions of intrathecal omega-conotoxins CVID, GVIA, MVIIA, and morphine in acute and neuropathic pain in the rat. Eur J Pharmacol 451 (2002) 279-286
36. Sharp D. Novel pain relief via marine snails. Lancet 366 (2005) 439-440
37. Wright C.E., Robertson A.D., Whorlow S.L., et al. Cardiovascular and autonomic effects of ω-conotoxins MVIIA and CVID in conscious rabbits and isolated tissue assays. Br J Pharmacol 131 (2000) 1325-1336
38. Kolosov A., Goodchild C.S., and Cooke I. CNSB004 (Leconotide) causes Antihyperalgesia without side effects when given intravenously: A comparison with ziconotide in a rat model of diabetic neuropathic pain. Pain Med 11 (2010) 262-273
39. Yunkger A.R., and McEnery M.W. Low-voltage-activated ("T-Type") calcium channels in review. J Bioenerg Biomembr 35 (2003) 533-575
40. Magee J.C., Christofi G., Miyakawa H., et al. Subthreshold synaptic activation of voltage-gated Ca2+ channels mediates a localized Ca2+ influx into the dendrites of hippocampal pyramidal neurons. J Neurophysiol 74 (1995) 1335-1342
41. Huguenard J.R. Low-threshold calcium currents in central nervous system neurons. Annu Rev Physiol 58 (1996) 329-348
42. Matthews E.A., and Dickenson A.H. Effects of ethosuximide, a T-type Ca2+ channel blocker, on dorsal horn neuronal responses in rats. Eur J Pharmacol 415 (2001) 141-149
43. Jagodic M.M., Pathirathna S., Nelson M.T., et al. Cell-specific alterations of T-type calcium current in painful diabetic neuropathy enhance excitability of sensory neurons. J Neurosci 27 (2007) 3305-3316
44. Jagodic M.M., Pathirathna S., Joksovic P.M., et al. Up-regulation of the T-type calcium current in small rat sensory neurons after chronic constrictive injury of the sciatic nerve. J Neurophysiol 99 (2008) 3151-3156
45. Bourinet E., Alloui A., Monteil A., et al. Silencing of the Cav3.2 T-type calcium channel gene in sensory neurons demonstrates its major role in nociception. EMBO J 24 (2005) 315-324
46. Wen X.J., Li Z.J., Chen Z.X., et al. Intrathecal administration of Cav3.2 and Cav3.3 antisense oligonucleotide reverses tactile allodynia and thermal hyperalgesia in rats following chronic compression of dorsal root of ganglion. Acta Pharmacol Sin 27 (2006) 1547-1552
47. v3.2 T-type channels. Genes Brain Behav 6 (2007) 425-431
48. Na H.S., Choi S., Kim J., et al. Attenuated neuropathic pain in Cav3.1 null mice. Mol Cells 25 (2008) 242-246
49. Kim D., Park D., and Choi S. Thalamic control of visceral nociception mediated by T-type Ca2+ channels. Science 302 (2003) 117-119
50. Dogrul A., Gardeli L.R., Ossipov M.H., et al. Reversal of experimental neuropathic pain by T-type calcium channel blockers. Pain 105 (2003) 159-168
51. Flatters S.J., and Bennett G.J. Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. Pain 109 (2004) 150-161
52. Barton M.E., Eberle E.L., and Shannon H.E. The antihyperalgesic effects of the T-type calcium channel blockers ethosuximide, trimethadione, and mibefradil. Eur J Pharmacol 521 (2005) 79-85
53. Gören M.Z., and Filiz O. Ethosuximide: From bench to bedside. CNS Drug Res 13 (2007) 224-239
54. Fossat P., Dobremez E., Bouali-Benazzouz R., et al. Knockdown of L calcium channel subtypes: Differential effects in neuropathic pain. J Neurosci 30 (2010) 1073-1085
55. 2+ channel subtypes on rat spinal motor neurons, interneurons, and nerve terminals. J Neurosci 18 (1998) 6319-6330
56. Fukumoto N., Obama Y., Kitamura N., et al. Hypoalgesic behaviors of P/Q-type voltage-gated Ca2+ channel mutant mouse, rolling mouse Nagoya. Neuroscience 160 (2009) 165-173
57. 1 subunits in the dorsal horn of spinal cord in mice. Brain Res 1024 (2004) 122-129
58. Saegusa H., Kurihara T., Zong S., et al. Altered pain responses in mice lacking α1E subunit of the voltage-dependent Ca2+ channel. Proc Natl Acad Sci USA 97 (2000) 6132-6137
59. Newcomb R., Szoke B., Palma A., et al. Selective peptide antagonist of the class E calcium channel from the venom of the tarantula Hysterocrates gigas. Biochimie 37 (1998) 15353-15362
60. Matthews E.A., Bee L.A., Stephens G.J., et al. The Cav2.3 calcium channel antagonist SNX-482 reduces dorsal horn neuronal responses in a rat model of chronic neuropathic pain. Eur J Neurosci 25 (2007) 3561-3569
61. Satzinger G. Antiepileptics from gamma-aminobutyric acid. Arzneim Forsch 44 (1994) 261-266
62. Hoekstra M.S., Sobieray D.M., Schwindt M.A., et al. Chemical development of CI-1008, an enantiomerically pure anticonvulsant. Org Proc Res Dev 1 (1997) 26-38
63. Meldrum B.S. GABAergic mechanisms in the pathogenesis of epilepsy. Br J Clin Pharmacol 27 (1989) 3S-11S
64. 2δ subunit of a calcium channel. J Biol Chem 271 (1996) 5768-5776
65. Taylor C.P., Gee N.S., Su T.-Z., et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 29 (1998) 231-246
66. Rosner H., Rubin L., and Kestenbaum A. Gabapentin adjunctive therapy in neuropathic pain states. Clin J Pain 12 (1996) 56-58
67. Mellick G.A., and Mellick L.B. Reflex sympathetic dystrophy treated with gabapentin. Arch Phys Med Rehabil 78 (1997) 98-105
68. Hwang J.H., and Yaksh T.L. Effect of subarachnoid gabapentin on tactile-evoked allodynia in a surgically induced neuropathic pain model in the rat. Reg Anesth Pain Med 22 (1997) 249-256
69. Brust P.F., Simerson S., McCue A.F., et al. Human neuronal voltage-dependent calcium channels: Studies on subunit structure and role in channel assembly. Neuropharmacology 32 (1993) 1089-1102
70. Yusaf S.P., Goodman J., Pinnock R.D., et al. Expression of voltage-gated calcium channel subunits in rat dorsal root ganglion neurons. Neurosci Lett 311 (2001) 137-141
71. 2δ subunits-Structure and gabapentin binding. Mol Pharmacol 59 (2001) 1243-1248
72. 2δ calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. J Neurosci 21 (2001) 1868-1875
73. 2δ-1 subunit up-regulation in rat neuropathic pain models correlates with antiallodynic effects of gabapentin. J Pharmacol Exp Ther 303 (2002) 1199-1205
74. 2δ -1 subunit upregulation contributes to peripheral nerve injury-induced tactile allodynia. J Neurosci 24 (2004) 8494-8499
75. 2δ1 subunit mediates spinal hyperexcitability in pain modulation. Pain 125 (2006) 20-31
76. Field M.J., Holloman E.F., McCleary S., et al. Evaluation of gabapentin and S-(+)-isobutyl GABA in a rat model of postoperative pain. J Pharmacol Exp Ther 282 (1997) 1242-1246
77. Field M.K., Oles R.J., Lewis A.S., et al. Gabapentin (Neurontin) and S-(+)-3-isobutyl GABA represent a novel class of selective anti-hyperalgesic agents. Br J Pharmacol 121 (1997) 1513-1522
78. 2δ ligand gabapentin. Proc Natl Acad Sci USA 105 (2008) 3628-3633
79. 2δ-1 to presynaptic terminals in neuropathic pain is inhibited by the a2d ligand Pregabalin. J Neurosci 29 (2009) 4076-4088
80. Vega-Hernandez A., and Felix R. Down-regulation of N-type voltage-activated channels by gabapentin. Cell Mol Neurobiol 22 (2002) 185-190
81. Bayer K., Ahmadi S., and Zeilhofer H.U. Gabapentin may inhibit synaptic transmission in the mouse spinal cord dorsal horn through a preferential block of P/Q-type calcium channels. Neuropharmacology 46 (2004) 743-749
82. Dworkin R.H., O'Connor A.B., Backonja M., et al. Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain 132 (2007) 237-251
83. Crofford L.J., Rowbotham M.C., Mease P.J., et al. Pregabalin for the treatment of fibromyalgia syndrome: Results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52 (2005) 1264-1273
84. Mease P.J., Russel I.J., Arnold L.M., et al. A randomized, double-blind, placebo-controlled, phase III trial of Pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 35 (2008) 502-514